PROTARA THERAPEUTICS INC (TARA) — insider trading
Health Care · NASDAQ
PROTARA THERAPEUTICS INC (TARA) has 18 reported SEC Form 4 insider transactions in our data, including 3 open-market sales among the most recent 18 (latest 2026-06-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Shefferman Jesse | Director, Officer (CEO and President) | Bona fide gift | 5,000 | — | $0 | Form 4 |
| 2026-06-30 | Shefferman Jesse | Director, Officer (CEO and President) | Bona fide gift | 4,000 | — | $0 | Form 4 |
| 2026-06-30 | Shefferman Jesse | Director, Officer (CEO and President) | Bona fide gift | 7,000 | — | $0 | Form 4 |
| 2026-06-30 | Shefferman Jesse | Director, Officer (CEO and President) | Bona fide gift | 14,000 | — | $0 | Form 4 |
| 2026-06-29 | Shefferman Jesse | Director, Officer (CEO and President) | Option exercise / conversion (derivative) | 215,687 | — | $0 | Form 4 |
| 2026-06-29 | Shefferman Jesse | Director, Officer (CEO and President) | Open-market sale | 215,687 | $4.09 | $882.2K | Form 4 |
| 2026-06-29 | Shefferman Jesse | Director, Officer (CEO and President) | Option exercise / conversion | 215,687 | $1.91 | $412.0K | Form 4 |
| 2026-06-15 | BESHAR LUKE M | Director | Grant / award / vesting (derivative) | 31,000 | — | $0 | Form 4 |
| 2026-06-15 | Flannelly Barry P | Director | Grant / award / vesting (derivative) | 31,000 | — | $0 | Form 4 |
| 2026-06-15 | GARCEAU ROGER | Director | Grant / award / vesting (derivative) | 31,000 | — | $0 | Form 4 |
| 2026-06-15 | Huang Jane | Director | Grant / award / vesting (derivative) | 31,000 | — | $0 | Form 4 |
| 2026-06-15 | SARGEN GREGORY | Director | Grant / award / vesting (derivative) | 31,000 | — | $0 | Form 4 |
| 2026-06-15 | Smith Cynthia | Director | Grant / award / vesting (derivative) | 31,000 | — | $0 | Form 4 |
| 2026-06-15 | Solomon Michael Edward | Director | Grant / award / vesting (derivative) | 31,000 | — | $0 | Form 4 |
| 2026-06-15 | Levy Richard S | Director | Grant / award / vesting (derivative) | 31,000 | — | $0 | Form 4 |
| 2026-06-02 | CONKLING WILLIAM | Officer (Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 6,008 | $4.34 | $26.1K | Form 4 |
| 2026-04-08 | Zummo Jacqueline | Officer (Chief R&D Officer) | Open-market sale | 1,134 | $5.40 | $6.1K | Form 4 |
| 2026-04-01 | Zummo Jacqueline | Officer (Chief R&D Officer) | Open-market sale | 22,598 | $5.26 | $118.9K | Form 4 |
Ask the chat about TARA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: PROTARA THERAPEUTICS INC (TARA).
Last updated 2026-06-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.